NT PHARMA: (1) VERY SUBSTANTIAL DISPOSAL IN RELATION TO THE PROPOSED DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL OF NT PHARMA INTERNATIONAL; (2) VERY SUBSTANTIAL ACQUISITIONIN RELATION TO THE PROPOSED ACQUISITION OF 40% EQUITY INTERESTS IN KANGCHEN; AND

HKEX · Jun 5, 2020 06:12

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

泰凌醫藥：(1) 非常重大出售事項關於可能出售泰凌醫藥國際全部已發行股本；(2) 非常重大收購事項關於可能收購康辰之40%股權；及 (3) 股東特別大會通告

NT PHARMA: (1) VERY SUBSTANTIAL DISPOSAL IN RELATION TO THE PROPOSED DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL OF NT PHARMA INTERNATIONAL; (2) VERY SUBSTANTIAL ACQUISITIONIN RELATION TO THE PROPOSED ACQUISITION OF 40% EQUITY INTERESTS IN KANGCHEN; AND

Risk Disclaimer

Statement